View More Recent Stories
-
Allogene Therapeutics (ALLO) to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases
-
Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS
-
Piper Sandler Reiterates Overweight Rating on Allogene (ALLO)
-
Piper Sandler Reiterates Overweight Rating on Allogene (ALLO)

